Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Old gout drug could help people taper off opioids

NCT ID NCT04939623

Symptom relief Sponsor: University of Calgary Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether probenecid, a drug currently used for gout, can reduce withdrawal symptoms in people with chronic pain who are voluntarily lowering their opioid dose. Researchers will enroll 40 adults and randomly assign them to take probenecid or a placebo for 12 weeks. The main goal is to see if probenecid is safe and tolerable in this group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Probenecid
What this could lead to
If it works, this could provide a safe, existing drug to help people with chronic pain reduce their opioid use more comfortably.
What could go wrong
This is a small early-phase pilot study focused on safety and tolerability, not yet on effectiveness. The drug may not reduce withdrawal symptoms significantly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults with chronic pain. Age greater than or equal to 18 years on the day of enrolment. 2. Subjects are currently taking a daily opioid pain medication and planning to taper the dose. 3. Participants complete at least one voluntary opioid dose reduction in the twelve-week study period. 4. Glomerular filtration rate (GFR) \> 50 mL/min 5. Capable of providing informed consent Exclusion Criteria: 1. Allergy to probenecid or related drugs 2. History of uric acid renal calculi, if known to be urate calculi. If unknown type, then any history of renal calculi. 3. Known G6PD deficiency 4. Active gout in any joint 5. Current use of drugs whose exposure may be prolonged, or risk of toxicity increased when used in combination with probenecid: 1. Penicillins, specifically ampicillin, penicillin G sodium, and piperacillin 2. Carbapenems, specifically doripenem and meropenem 3. Lorazepam, midazolam, nitrazepam 4. Ketorolac 5. Oseltamivir 6. Methotrexate 7. Mycophenolate 6. Current use of drugs which may mask symptoms of withdrawal: a. Clonidine, lofexidine, tizanidine 7. Current use of drugs which may diminish the effect of probenecid: a. High dose salicylates including greater than 325 mg PO daily of acetylsalicylic acid (ASA) 8. Pregnancy or breastfeeding 9. Any major comorbid medical condition which might impair follow-up or result in a safety risk to the participant 10. Participation in another clinical trial investigating a drug, medical device, or a medical procedure during the 30 days prior to enrolment. \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Chronic Pain chronic pain syndrome morphine dependence opiate dependence substance withdrawal syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic pain Drug dependence of morphine type Symptom, withdrawal

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Richmond Road Diagnostic and Treatment Centre

    RECRUITING

    Calgary, Alberta, T2T 5C7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.